Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2016-05-08 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
ATL1103 Higher Dose Study - Update 2 pages 30.7KB
Regulatory Filings Classification · 90% confidence The document is an update on a clinical trial study (ATL1103 higher dose study) conducted by Antisense Therapeutics. It provides detailed information about the study design, patient dosing, safety, and plans for interim analysis. The content focuses on the progress and scientific details of the trial rather than financial results, regulatory certifications, or shareholder information. It is not a financial report, earnings release, regulatory filing, or management announcement. The document is a clinical trial update, which typically falls under general regulatory announcements or company updates. Given the absence of financial data or formal report structure, and the nature of the content as a progress update, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other categories.
2016-05-08 English
ATL1103 Deed of Settlement, Termination and Transfer 1
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 29th April 2016 from Antisense Therapeutics Limited regarding a Deed of Settlement, Termination and Transfer with Strongbridge Biopharma. It details the termination of a License Agreement, payment terms, share cancellation, and transfer of drug compounds and data. The content is focused on a specific transaction and settlement agreement rather than financial results, regulatory filings, or management changes. The document length is 3201 characters, which is relatively short and reads like a formal announcement rather than a detailed report. There is no indication of financial statements, audit information, or meeting materials. Therefore, this document fits best under the category of Capital/Financing Update (CAP), as it relates to a significant financing and capital structure event involving share cancellation and settlement payment.
2016-04-28 English
Appendix 4C - quarterly 5 pages 39.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Report for Entities Admitted on the Basis of Commitments' and references a quarter ended 31 March 2016. It contains detailed financial data including cash flows from operating, investing, and financing activities, reconciliation of cash, payments to directors, and compliance statements. The document is over 7,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with a quarterly financial report providing actual financial statements and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2016
2016-04-21 English
COR-004/ATL1103 Project Update 5 pages 139.0KB
Capital/Financing Update Classification · 95% confidence The document is a corporate update and press release from Antisense Therapeutics and its licensing partner Strongbridge Biopharma. It provides information on the return of a drug candidate ATL1103 to Antisense, updates on clinical trials, regulatory feedback, cash position, and strategic prioritization of drug development. There are no financial statements, no detailed financial performance data, no earnings highlights, no voting results, no management or board changes, no legal proceedings, no merger or acquisition details, and no regulatory certifications. The document is a corporate progress update and operational status announcement, typical of a Capital/Financing Update or general corporate update. Given the focus on project updates, licensing, and cash position, the best fitting category is Capital/Financing Update (CAP). The document length is substantial and contains detailed operational and financial resource information, supporting this classification with high confidence.
2016-03-08 English
Trading Halt 1 page 223.9KB
Regulatory Filings Classification · 95% confidence The document is a market release announcing a trading halt for Antisense Therapeutics Limited securities. It is a short announcement about the suspension of trading pending a future announcement. There is no financial data, report, or detailed information provided. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement related to trading status and compliance, not a financial report or other specific filing type.
2016-03-06 English
Trading Halt Request 1 page 203.3KB
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the ASX Compliance office requesting a trading halt for Antisense Therapeutics Limited. It references ASX Listing Rule 17.1 and states the reason for the halt is pending an announcement related to the ATL1103 program. The document is short (1334 characters) and does not contain any financial data, report content, or detailed disclosures. It is clearly an announcement related to trading status rather than a financial report or other filing type. Therefore, it fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2016-03-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.